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Gemfibrozil for secondary prevention of cardiovascular events
in mild to moderate chronic renal insufficiency.
Background. Although cardiovascular disease and low high-
density lipoprotein (HDL) cholesterol are common in people
with renal insufficiency, data addressing the cardiovascular ben-
efits of fibric acid derivatives in this population are sparse.
We conducted a post hoc subgroup analysis of a randomized
double-blind, placebo-controlled trial to determine whether
gemfibrozil is effective and safe for secondary prevention of
cardiovascular events in individuals with chronic renal insuffi-
ciency (CRI).
Methods. Using an analysis plan that was developed a pri-
ori, we analyzed data from the Veterans’ Affairs High-Density
Lipoprotein Intervention Trial (VA-HIT) study; a randomized
trial of gemfibrozil versus placebo in 2531 men with estab-
lished coronary disease, an HDL cholesterol level of 40 mg/dL
(1.0 mmol/L) or less, and a low-density lipoprotein (LDL)
cholesterol level of 140 mg/dL (3.6 mmol/L) or less. Of
these, 1046 men had CRI as defined by creatinine clearance
≤75 mL/min using the Cockcroft-Gault equation, 99.8% of
whom had either mild or moderate renal impairment (crea-
tinine clearance 60–75 or 30–59.9 mL/min, respectively).
Results. The incidence of the primary outcome (coronary
death or nonfatal myocardial infarction) was lower in partic-
ipants with CRI who received gemfibrozil compared to placebo
[hazard ratio (HR) 0.73; 95% CI 0.56–0.96, P = 0.02). The cu-
mulative incidence of the primary end point was reduced from
24.3% to 18.2%. In subjects with CRI, gemfibrozil also signif-
icantly reduced the risk of the combined outcome of coronary
death, nonfatal myocardial infarction, or stroke (HR 0.74, 95%
CI 0.58–0.95, P = 0.02), but not the need for coronary revas-
cularization (HR 0.85, 95% CI 0.66–1.10, P = 0.21) or total
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mortality (HR 1.03, 95% CI 0.78–1.35, P = 0.85). The over-
all incidence of adverse effects was similar in individuals re-
ceiving gemfibrozil and placebo. However, the risk of sustained
increases in serum creatinine was increased in gemfibrozil re-
cipients compared with placebo (5.9 vs. 2.8%, P = 0.02).
Conclusion. Gemfibrozil appears effective for secondary pre-
vention of cardiovascular events in individuals with mild to
moderate chronic renal insufficiency and HDL cholesterol of
40 mg/dL or less. However, the benefit and safety of gemfibrozil
in people with more severe impairment of kidney function re-
quires further study.
Chronic renal insufficiency (CRI) is a common condi-
tion that affects at least six million American people [1].
Individuals with CRI have cardiovascular mortality rates
that are substantially higher than those of the general
population [2], and renal insufficiency is an independent
predictor of mortality among individuals with coronary
disease (CVD) or multiple cardiovascular risk factors
[3, 4].
HMG-Co-A reductase inhibitors (statins) are effec-
tive for secondary prevention of cardiovascular events
in people with mild to moderate renal insufficiency [5].
Statins substantially lower total and low-density lipopro-
tein (LDL) cholesterol, but affect concentrations of high-
density lipoprotein (HDL) cholesterol and triglycerides
to a much lesser degree. However, the classic lipid profile
of individuals with moderate to severe CRI is character-
ized by low levels of HDL cholesterol and high levels
of serum triglycerides rather than hypercholesterolemia.
Although few data are available about dyslipidemia in
people with milder renal dysfunction, therapies that in-
crease HDL cholesterol might be particularly relevant
for people with chronic kidney disease.
Fibric acid derivatives (fibrates) raise HDL cholesterol
and lower triglyceride levels, and reduce cardiovascular
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event rates among those with low HDL cholesterol and
documented coronary disease [7]. On the other hand,
concern has been raised about potential toxicity of fi-
brates, especially in people with kidney disease [8]. We
analyzed data from a randomized placebo-controlled trial
to determine the efficacy and safety of gemfibrozil in peo-
ple with mild to moderate CRI.
METHODS
Study group and design
The design of the Veterans’ Affairs High-Density
Lipoprotein Intervention Trial (VA-HIT) has been
described in detail elsewhere [9]. Briefly, men were re-
cruited at 20 Veterans’ Affairs medical centers through-
out the United States. Eligibility for the trial required a
documented history of coronary heart disease (previous
myocardial infarction, angina corroborated by objective
evidence of ischemia, coronary revascularization, or an-
giographic evidence of stenosis greater than 50% of the
luminal diameter in one or more major epicardial coro-
nary arteries), an age of less than 74 years, an HDL choles-
terol level ≤40 mg/dL (1.0 mmol/L), an LDL cholesterol
level ≤140 mg/dL (3.6 mmol/L), and a triglyceride level
≤300 mg/dL (3.4 mmol/L). To obtain a population whose
lipid values were at or below these levels, a multistage
lipid-screening method was used that included two lipid
profiles obtained one to two weeks apart while the sub-
jects were fasting. Two additional fasting profiles were
used for the baseline lipid values. Participants with serum
creatinine values >2.0 mg/dL were specifically excluded
from the VA-HIT study.
Subjects were randomly assigned to receive either
gemfibrozil (1200 mg per day; Parke-Davis, Ann Ar-
bor, MI, USA) or matching placebo, according to a
permuted-block design with stratification according to
center. Throughout the trial, all subjects and local study
personnel were blinded to treatment assignment. No
changes were made to other prescription medications
that participants were receiving at baseline (Table 1).
Ascertainment of outcomes
In this analysis, we used the same cardiovascular end
points as specified by the VA-HIT protocol. The pri-
mary end point was death from coronary disease (in-
cluding fatal myocardial infarction, sudden death, death
during a coronary intervention, and death from other
coronary causes) or a nonfatal myocardial infarction. Sec-
ondary end points included major cardiovascular events
(fatal coronary disease, nonfatal myocardial infarction, or
stroke), all-cause mortality, stroke, and coronary revascu-
larization. The occurrence of myocardial infarction, coro-
nary death, and stroke were ascertained by committees
that were blinded to serum lipid levels and treatment
assignment; all other outcomes were ascertained by the
principal investigator at each study site.
For all cardiovascular outcomes, standardized prespec-
ified definitions were used. We defined adverse events as
originally reported in the VA-HIT study. However, be-
cause of concern that gemfibrozil might be nephrotoxic
we also evaluated the relative incidence of two adverse
events that were not previously reported, concerning the
effect of gemfibrozil on serum creatinine. In these anal-
yses, a clinically relevant increase in serum creatinine
was defined by a rise of ≥0.5 mg/dL from baseline. Tran-
sient increases by definition were followed by subsequent
serum creatinine values that were <0.5 mg/dL higher than
baseline. Sustained increases were those in which serum
creatinine values remained ≥0.5 mg/dL higher than base-
line for the remainder of follow-up.
Definitions of renal insufficiency
The Cockcroft-Gault estimate of creatinine clearance
is widely used and correlates well with glomerular filtra-
tion rate (GFR) [10]. The primary definition of CRI in
this analysis was selected a priori as creatinine clearance
≤75 mL/min. Because subjects with serum creatinine val-
ues >2.0 mg/dL were excluded, it was expected that the
study population would consist mostly of those with mild
(creatinine clearance 60 to 75 mL/min) and moderate
(creatinine clearance 30 to 59.9 mL/minute) renal insuf-
ficiency. Serum creatinine measurements were made an-
nually on participants by individuals who were blinded to
treatment assignment. Measurements were made at lab-
oratories located at each of the 20 study centers, using a
variety of autoanalyzers.
Recently published guidelines suggest defining renal
function in terms of an equation derived from the Modi-
fication of Diet in Renal Disease Study (MDRD-GFR).
This equation expresses results in mL/min/1.73 m2 body
surface area (BSA), and is defined by:
186 × PCr1.154 × age in years−0.203 × 1.210 (if black)
× 0.742 (if female),
where PCr is plasma creatinine in mg/dL [11]. These
guidelines define mildly decreased GFR as MDRD-GFR
of 60 to 89 mL/min/1.73 m2 [11]. We performed ad-
ditional analyses, defining mild CRI as MDRD-GFR
≤75 mL/min/1.73 m2.
Statistical analysis
All hazard ratios (HR) and associated 95% CI were
estimated from Cox proportional hazards models, ad-
justing for covariates that might confound the relation
between treatment assignment and outcomes [age, his-
tory of hypertension, smoking status, diabetes mellitus,
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Table 1. Baseline characteristics in participants according to creatinine clearance and treatment status
Creatinine clearance Creatinine clearance Creatinine clearance Creatinine clearance
>75 mL/min ≤75 mL/min ≤75 mL/min ≤75 mL/min
Variable (N = 1459) (N = 1046) placebo (N = 534) gemfibrozil (N = 512)
Age years 61.7 ± 7.6 67.5 ± 5.0 67.3 ± 4.8 67.7 ± 5.2
White race 1342 (92.0%) 902 (86.2%) 463 (86.7%) 439 (85.7%)
History of chronic heart failure 116 (8.0%) 84 (8.0%) 40 (7.5%) 44 (8.6%)
History of hypertension 824 (56.5%) 604 (57.7%) 306 (57.3%) 298 (58.2%)
Diabetes mellitus 464 (31.8%) 297 (28.4%) 161 (30.2%) 136 (26.6%)
Current smoker 330 (22.6%) 179 (17.1%) 95 (17.8%) 84 (16.4%)
Body surface area m2 2.2 ± 0.2 2.0 ± 0.2 2.0 ± 0.16 2.0 ± 0.15
Medication use
Gemfibrozil 739 (50.7%) 512 (49.0%) 0 (0%) 512 (100%)
ACE inhibitor 299 (20.5%) 227 (21.7%) 113 (21.2%) 114 (22.3%)
Aspirin 1194 (81.8%) 849 (81.2%) 439 (82.2%) 410 (80.1%)
Beta-adrenergic blocker 617 (42.3%) 469 (44.8%) 228 (42.7%) 241 (47.1%)
Lipid status
Total cholesterol in mmol/L mg/dL 4.5 ± 0.6 (175.4 ± 24.4) 4.5 ± 0.7 (173.5 ± 25.2) 4.5 ± 0.6 (173.4 ± 24.2) 4.5 ± 0.7 (173.5 ± 26.2)
LDL cholesterol in mmol/L mg/dL 2.9 ± 0.6 (111.4 ± 22.3) 2.9 ± 0.6 (110.4 ± 22.2) 2.9 ± 0.6 (110.7 ± 22.0) 2.9 ± 0.7 (110.3 ± 26.2)
HDL cholesterol in mmol/L mg/dL 0.8 ± 0.1 (31.4 ± 5.4) 0.8 ± 0.1 (31.7 ± 5.3) 0.8 ± 0.1 (31.7 ± 5.2) 0.8 ± 0.1 (31.7 ± 5.4)
Triglyceride in mmol/L mg/dL 1.7 ± 1.0 (154.5 ± 88.0) 1.6 ± 1.0 (145.5 ± 91.0) 1.7 ± 1.1 (147.0 ± 95.0) 1.6 ± 1.0 (142.5 ± 87.5)
(median ± interquartile range)
Renal function and blood pressure
Creatinine clearance mL/min 100.4 ± 32.1 61.5 ± 9.6 61.8 ± 12.3 61.2 ± 12.2
MDRD-GFR 81.8 ± 23.3 61.6 ± 12.0 62.0 ± 11.8 61.2 ± 12.2
Systolic blood pressure mm Hg 132.0 ± 18.1 132.3 ± 19.1 132.6 ± 19.3 132.0 ± 19.3
Diastolic blood pressure mm Hg 77.8 ± 10.1 76.5 ± 10.4 76.7 ± 10.4 76.2 ± 10.5
Values are mean ± SD unless otherwise specified. Creatinine clearance was calculated using the Cockcroft-Gault formula [10]. MDRD-GFR was calculated using
186 × PCr−1·154 × age in years −0·203 × 1.210 (if black) × 0.742 (if female), where PCr is plasma creatinine in mg/dL [11].
prior chronic heart failure (CHF), use of angiotensin-
converting enzyme inhibitors, beta-adrenergic blockers,
and aspirin, systolic and diastolic blood pressure, HDL
cholesterol, LDL cholesterol, triglycerides, BSA]. There
was no evidence that the proportional hazards assump-
tion was violated on review of the log-log survival curves
for each model. We also performed several additional
analyses to evaluate the potential interactions between
gemfibrozil use, CRI, and certain subgroups, using pub-
lished recommendations for such analyses [12]. We spec-
ified all subgroups and all the covariates used in the Cox
models a priori. Analyses were performed using SAS sta-
tistical software, version 8.2 (Cary, NC, USA). Partici-
pants were analyzed in the groups to which they were
randomized. Two-sided P values of <0.05 were consid-
ered to represent statistical significance.
Role of the funding source
The VA-HIT trial was an investigator-initiated study
funded by the Cooperative Studies Program of the De-
partment of Veterans Affairs Office of Research and by a
supplemental grant from Parke-Davis. The pharmaceuti-
cal company was not involved in analyses or the decision
to submit the manuscript for consideration. The authors
had full access to all the data in the study, and take re-
sponsibility for the integrity of the data and the accuracy
of the data analysis.
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Figure 1. Flow of participants. For inclusion criteria, see text.
RESULTS
Baseline characteristics
Creatinine clearance could be calculated for 2505/2531
(99.0%) of the men in the original trial. Of these, 1046
(42.1%) had CRI as defined by creatinine clearance
≤75 mL/min (Fig. 1). Participants with renal insufficiency
were older, more likely to have a history of hypertension
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Table 2. Effect of gemfibrozil use on incidence of cardiovascular events and mortality in participants with chronic renal insufficiency as defined
by creatinine clearance ≤75 mL/min
Placebo (N = 529) Gemfibrozil (N = 508) Adjusted hazard ratio
No. of Cumulative No. of Cumulative with gemfibrozil
Event participants incidence (%) participants incidence (%) (95% CI) P value
Death from CHD or nonfatal MI 130 24.6 93 18.3
Major cardiovascular eventa 154 29.1 112 22.0 0.75 (0.59–0.96) 0.02
Total mortality 106 20.0 107 21.1 1.05 (0.80–1.37) 0.75
Nonfatal MI 82 15.5 58 11.4 0.72 (0.52–1.01) 0.06
CABG or PTCA 133 25.1 107 21.1 0.80 (0.62–1.04) 0.10
Cardiovascular death 63 11.9 47 9.3 0.77 (0.53–1.13) 0.19
Stroke 38 7.2 29 5.7 0.80 (0.49–1.30) 0.36
Abbreviations are: CHD, coronary heart disease; MI, myocardial infarction; CABG, coronary-artery bypass grafting; PTCA, percutaneous transluminal coronary
angioplasty. Hazard ratios and P values were derived from Cox proportional-hazards models. Hazard ratios have been adjusted for age, history of hypertension, smoking
status, diabetes mellitus, prior CHF, use of angiotensin-converting enzyme inhibitors, beta-adrenergic blockers and aspirin, systolic and diastolic blood pressure, HDL
cholesterol, LDL cholesterol, triglycerides, and body surface area. Among participants with renal insufficiency, five participants in the placebo group and four in the
gemfibrozil group had missing values for covariates and were not included in the Cox models.
aMajor cardiovascular event is a composite outcome of fatal CHD, nonfatal myocardial infarction, and stroke.
or chronic heart failure, and had smaller BSA than those
without. Characteristics of individuals assigned to gem-
fibrozil and to placebo in the subgroup with renal insuf-
ficiency were similar at baseline (Table 1). Of the 1046
subjects with renal insufficiency, 638 (61.0%) had crea-
tinine clearance 60 to 75 mL/min and 406 (38.8%) had
creatinine clearance between 30 and 59.9 mL/min. Two
subjects had creatinine clearance <30 mL/min.
Use of comedications
Rates of beta-adrenergic blocker, aspirin, and
angiotensin-converting enzyme inhibitor use were sim-
ilar between treatment groups at baseline. Angiotensin-
receptor antagonists were not widely used at the time
the VA-HIT study was conducted, and no participants
received hypolipemic medications other than the study
agent.
Cardiovascular event rates in CRI
The crude cumulative incidence rates of the primary
end point and major cardiovascular events were in-
creased in individuals with CRI compared to those
without. There were 223/1046 individuals with renal insuf-
ficiency (21.3%) who experienced the primary end point
compared with 268/1459 (18.4%) without renal insuffi-
ciency (HR 1.20, CI 1.01-1.43). Participants with CRI also
had higher crude rates of all-cause mortality, cardiovas-
cular mortality, and stroke. Adjustment for potential con-
founders did not qualitatively alter the relation between
renal insufficiency and cardiovascular events, although
the increased risk associated with renal insufficiency was
nonsignificant [adjusted HR of the primary outcome 1.21
(0.97–1.50)].
Effect of gemfibrozil use on lipid parameters in CRI
Median duration of follow-up in the participants with
CRI was 5.3 years, and complete follow-up was available
for all participants with CRI. Individuals with and without
renal insufficiency had similar changes in plasma lipids in
response to gemfibrozil during the study. Among those
with renal insufficiency, gemfibrozil was associated with
reductions in triglycerides of 0.6 mmol/L (56.4 mg/dL,
P < 0.0001), mean total cholesterol of 0.2 mmol/L
(7.1 mg/dL, P < 0.0001), and an increase in HDL choles-
terol of 0.06 mmol/L (2.34 mg/dL, P < 0.0001), all com-
pared with placebo. Gemfibrozil did not significantly
affect mean LDL cholesterol (P = 0.18).
Effect of gemfibrozil on cardiovascular outcomes in CRI
Gemfibrozil use was associated with a lower rate of
cardiovascular events in CRI, even after adjusting for po-
tential confounders (Table 2). Participants with renal in-
sufficiency who received gemfibrozil had an adjusted HR
of 0.74 (95% CI 0.56-0.96) for the primary end point of
fatal coronary disease or myocardial infarction. The ab-
solute reduction in the rate of the primary end point was
6.1%, corresponding to a number-needed-to-treat of 16.
The cumulative incidence of major cardiovascular events
(nonfatal myocardial infarction, fatal coronary disease,
or stroke) was also reduced by gemfibrozil treatment (ad-
justed HR 0.75, 95% CI 0.59-0.96). Rates of nonfatal my-
ocardial infarction (adjusted HR 0.72, 95% CI 0.52-1.01),
coronary revascularization (HR 0.80, 95% CI 0.62-1.04),
stroke (HR 0.80, 95% CI 0.49-1.30), and total mortality
(adjusted HR 1.05, 95% CI 0.80–1.37) were not signifi-
cantly reduced by gemfibrozil use.
Alternate definition of CRI
We repeated our analysis concerning major cardio-
vascular events using MDRD-GFR ≤75 mL/min/1.73m2
to define renal insufficiency (N = 1432). The magni-
tude of benefit associated with gemfibrozil use was sim-
ilar in this subgroup compared with those who had
CRI by the primary definition. Among individuals with
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Table 3. Major cardiovascular events in subgroups of participants with chronic renal insufficiency, defined by baseline variables
No. of participants
No. of participants with event (%) Adjusted hazard
Variable Placebo Gemfibrozil Placebo Gemfibrozil ratio (95% CI)
Diabetes mellitus
Present 161 136 66 (41.0) 36 (26.5) 0.58 (0.38–0.89)
Absent 373 376 88 (23.6) 76 (20.2) 0.88 (0.64–1.20)
Total cholesterol
≤4.0 mmol/L (<174 mg/dL) 269 261 77 (28.6) 46 (17.6) 0.56 (0.39–0.82)
>4.0 mmol/L (≥174 mg/dL) 263 248 77 (29.3) 66 (26.6) 0.93 (0.67–1.31)
LDL cholesterol
<2.6 mmol/L (<112 mg/dL) 260 260 71 (27.3) 50 (19.2) 0.66 (0.46–0.96)
>2.6 mmol/L (≥112 mg/dL) 269 248 81 (30.1) 62 (25.0) 0.84 (0.60–1.17)
HDL cholesterol
≤0.7 mmol/L (<32 mg/dL) 261 234 87 (33.3) 56 (23.9) 0.71 (0.51–0.99)
>0.7 mmol/L (≥32 mg/dL) 271 276 67 (24.7) 56 (20.3) 0.87 (0.61–1.25)
Triglycerides
<1.6 mmol/L (<146 mg/dL) 262 261 72 (27.5) 54 (20.7) 0.67 (0.47–0.97)
≥1.6 mmol/L (≥146 mg/dL) 270 249 82 (30.4) 58 (23.3) 0.82 (0.58–1.15)
Creatinine clearance
60–75 mL/min 332 306 97 (29.2) 62 (20.3) 0.70 (0.50–0.96)
<60 mL/min 202 206 57 (28.2) 50 (24.3) 0.85 (0.58–1.26)
MDRD-GFR
60–75 mL/min/1.73m2 229 206 60 (26.2) 40 (19.4) 0.79 (0.53–1.19)
<60 mL/min/1.73m2 228 242 75 (32.9) 58 (24.0) 0.72 (0.51–1.02)
Definition of renal insufficiency is creatinine clearance ≤75 mL/min unless otherwise specified. Major cardiovascular event was a composite outcome of fatal CHD,
nonfatal myocardial infarction, and stroke. Hazard ratios and P values were derived from Cox proportional-hazards models. Hazard ratios have been adjusted for age,
history of hypertension, smoking status, diabetes mellitus, prior CHF, use of angiotensin-converting enzyme inhibitors, beta-adrenergic blockers and aspirin, systolic
and diastolic blood pressure, HDL cholesterol, LDL cholesterol, triglycerides, and body surface area. Among participants with renal insufficiency, five participants in
the placebo group and four in the gemfibrozil group had missing values for covariates and were not included in the Cox models.
MDRD-GFR ≤75 mL/min/1.73m2, the adjusted hazard
ratio of the primary end point was 0.81 (95% CI 0.65-
1.02), and it was 0.82 (95% CI 0.67-1.03) for major car-
diovascular events.
Gemfibrozil use in subgroups of participants with CRI
We analyzed the effect of gemfibrozil use on cardio-
vascular events among subgroups of individuals with
CRI that were defined by baseline variables (Table 3).
There were no statistically significant interactions be-
tween any of these characteristics and the hazard ra-
tio associated with gemfibrozil use (P for interaction
>0.05 in all cases). In particular, there was no evidence
of a significant interaction between the presence or ab-
sence of renal insufficiency and the effect of gemfibrozil
(Table 3).
Adverse events
The frequency of therapy discontinuation was similar
between treatment groups among individuals with CRI in
terms of the primary definition (Table 4). The incidence
of noncoronary death was marginally increased in gemfi-
brozil recipients (P = 0.07), although total mortality was
equivalent between groups (P = 0.75).
Among those with renal insufficiency, there were no
significant differences in the number of participants in
gemfibrozil and placebo arms who experienced eleva-
tions in serum creatine phosphokinase levels greater than
three times the upper limit of normal, other abnormalities
in liver function tests, or rhabdomyolysis. The numbers of
participants with malignancy, depression, or who commit-
ted suicide were also similar between treatment groups
among those with renal insufficiency. Transient elevations
in serum creatinine (>0.5 mg/dL compared with baseline)
appeared to be more frequent among gemfibrozil recip-
ients, although this was not statistically significant (P =
0.07). However, the incidence of sustained elevations in
serum creatinine (>0.5 mg/dL compared with baseline)
was higher among gemfibrozil recipients compared with
placebo (5.9% vs. 2.8%, P = 0.02). Among those subjects
with sustained rises in serum creatinine, the final serum
creatinine levels (2.3 ± 0.5 vs. 2.6 ± 1.3 mg/dL) and crea-
tinine clearances (32.0 ± 8.5 vs. 31.9 ± 9.3 mL/min) were
similar in both groups (P = 0.43 and 0.94, respectively).
Among gemfibrozil recipients with sustained increases
in serum creatinine, mean baseline creatinine clearance
was 56.8 ± 12.3 mL/min, and none required acute dialysis
treatment.
DISCUSSION
CRI is associated with high rates of cardiovascular dis-
ease, which in turn is a major cause of morbidity and mor-
tality among individuals with kidney disease. We found
that gemfibrozil reduced the cumulative incidence of
cardiovascular death or myocardial infarction in people
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Table 4. Adverse events in participants with chronic renal insufficiency
Subjects with CRI Subjects without CRI
Placebo Gemfibrozil Gemfibrozil
(N = 534) (N = 512) P valuea (N = 752) P valueb
Discontinuation of study medication
Request by patient (side effect) 32 (6.0%) 43 (8.4%) .15 52 (7.0%) .37
Decision by physician (safety concern 6 (1.1%) 8 (1.6%) .57 9 (1.2%) .61
or adverse event)
Initiation of other lipid therapy 10 (1.9%) 14 (2.7%) .39 18 (2.4%) .74
Other 62 (11.6%) 55 (10.7%) .51 87 (11.8%) .57
Overall 110 (20.6%) 120 (23.4%) .30 166 (22.5%) .69
Other adverse events
Depression 20 (3.8%) 14 (2.7%) .35 21 (2.8%) .91
Suicide attempt 2 (0.4%) 1 (0.2%) .59 3 (0.4%) .52
Myositis 48 (9.0%) 35 (6.8%) .20 76 (10.3%) .04
Rhabdomyolysis 0 (0.0%) 0 (0.0%) – 0 (0.0%) –
Transaminitis 17 (3.2%) 20 (3.9%) .53 18 (2.4%) .14
Any creatinine rise of >0.5 mg/dL 19 (3.6%) 30 (5.9%) .08 20 (2.7%) .005
Malignancy 58 (10.9%) 52 (10.2%) .71 74 (10.0%) .93
Myositis was defined as follow-up creatine kinase values >3 times the baseline values. Transaminitis was defined as follow-up SGOT values >3 times the baseline
values.
aP value for comparison between placebo and gemfibrozil recipients, among those with CRI.
bP value for comparison between gemfibrozil recipients, with and without CRI.
with mild to moderate CRI. The absolute reduction in
the cumulative incidence of the primary end point was
6.1%, corresponding to a number-needed-to-treat of 16,
which compares favorably with the absolute risk reduc-
tion observed in VA-HIT participants without renal in-
sufficiency (3.2%, NNT 31). Treatment with gemfibrozil
also appeared to reduce the risk of coronary revascu-
larization, although this was not statistically significant.
Results were similar when MDRD-GFR, rather than cre-
atinine clearance, was used to define renal insufficiency.
There was no evidence that severity of renal dysfunction
or other clinical characteristics affected the magnitude of
benefit within the population studied.
It has been suggested that rates of fibrate-related
adverse events may be higher among individuals with
kidney disease [13, 14]. Gemfibrozil treatment was well
tolerated in this patient population, with similar rates of
adverse events and therapy discontinuation in treatment
and placebo groups. Although the overall rates of therapy
discontinuation were relatively high in both groups, these
proportions were similar to those in the entire VA-HIT
population. In the current study, the incidence of non-
coronary death was marginally increased in gemfibrozil
recipients, but total mortality was similar in both treat-
ment groups (HR 1.05, 95% CI 0.80-1.37).
Although transient and sustained increases in serum
creatinine occurred in both groups during follow-up,
the latter event was significantly more common in gem-
fibrozil recipients. This observation contradicts previ-
ous suggestions that gemfibrozil, unlike other fibrates,
does not acutely impair kidney function [15]. While the
mean increase in plasma creatinine was clinically relevant
(1.0 mg/dL overall), the absolute increase in the fre-
quency of this event among gemfibrozil recipients was
relatively small (5.9% vs. 2.8%, thus 3.1%). In addition,
among participants with sustained decrements in renal
function, the magnitude of the decrease appeared similar
between treatment groups. Although no participant re-
quired dialysis treatment, such impairment of renal func-
tion may be clinically relevant. We suggest that serum
creatinine should be closely monitored in patients with
mild to moderate CRI who receive fibrates. In addition,
it is important to note that the benefit and safety of gem-
fibrozil in people with severe renal dysfunction cannot be
determined from these data.
Although the MDRD-GFR equation has been exten-
sively validated in moderate to severe CRI [11, 16], its
accuracy at higher levels of renal function (as in most
VA-HIT participants) is not as well established. For this
reason, we chose a priori to primarily define renal in-
sufficiency in terms of creatinine clearance rather than
MDRD-GFR. Despite the well-known limitations of cre-
atinine clearance, all such individuals almost certainly
have impaired renal function, especially because the
Cockcroft-Gault equation tends to overestimate GFR.
Thus, we believe that we are justified in characterizing the
subjects in the current analysis as having mild to moder-
ate renal insufficiency.
We found that CRI was associated with increased crude
incidence rates of cardiovascular morbidity and mortality,
as in the Heart Outcomes Prevention Evaluation study
and elsewhere [3, 17–19]. In the current study, adjust-
ment for potential confounders produced little change
in the magnitude of the increased cardiovascular rela-
tive risk associated with renal insufficiency, although the
resulting CIs were wider. Interpretation of this work is
complicated by the lack of uniform adjustment for CHF
and proteinuria (which are known to be correlated with
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cardiovascular outcomes), and by slightly different defi-
nitions of renal insufficiency. Nonetheless, it is clear that
independent of age, individuals with renal insufficiency
constitute a readily identifiable group with high rates of
adverse clinical outcomes, even when renal dysfunction
is mild [20, 21]. Finally, because mortality rates among
individuals with acute myocardial infarction are signifi-
cantly higher in those who also have renal impairment,
prevention of cardiovascular events may be particularly
relevant in this population [4].
Data from the Cholesterol and Recurrent Events
(CARE) and Heart Protection (HPS) studies suggest that
statins are safe and effective for reducing cardiovascular
risk in people with mild to moderate renal insufficiency
[5, 22]. However, neither study addressed the manage-
ment of low HDL cholesterol in people with kidney dis-
ease. Our data show that fibrates improve cardiovascular
outcomes in the relatively common subgroup of people
with mild to moderate renal insufficiency and low HDL
and LDL cholesterol, suggesting that fibrates may be a
reasonable alternative to statins in this population.
To our knowledge, we are the first to present data from
a randomized trial evaluating the effect of fibrates on
cardiovascular outcomes in people with impaired kidney
function. However, the results of our study should be in-
terpreted with several potential limitations in mind. First,
all participants were male and had preexisting coronary
disease, and thus, our findings may not apply to females, or
to primary prevention. Second, we did not have informa-
tion about proteinuria or the etiology of renal dysfunction
in study participants. Third, people with serum creatinine
>2.0 mg/dL were excluded, and the study population did
not include a significant number of subjects with severe
renal insufficiency. Our findings may therefore not apply
to such individuals. These caveats undoubtedly reduce
the generalizability of our findings. Nonetheless, we be-
lieve that the current study is a useful addition to the
literature because dyslipidemia, renal insufficiency, and
coronary disease is a combination that is frequently en-
countered in clinical practice, and, regrettably, is associ-
ated with high cardiovascular event rates.
Because serum creatinine measurements were not
standardized between centers, or calibrated against a ref-
erence standard, it is possible that misclassification of
some subjects occurred with respect to CRI. Also, al-
though the duration of low creatinine clearance at base-
line in VA-HIT participants was unknown, we have used
the term “chronic renal insufficiency.” Given the very low
frequency of acute renal failure in individuals such as
those in clinical trials, the assumption that baseline renal
impairment was chronic appears reasonable. Finally, re-
nal function was defined by prediction equations based
on serum creatinine, rather than direct measurements of
GFR. However, the results were consistent using both es-
timated creatinine clearance and MDRD-GFR, making
it unlikely that another marker of renal function would
have changed our results.
CONCLUSION
Gemfibrozil is effective for secondary prevention of
cardiovascular events in individuals with mild to moder-
ate CRI and low HDL cholesterol levels. However, the
benefit and safety of gemfibrozil in people with severe
renal dysfunction require further study.
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